Brief: Dermata Therapeutics Inc - Announces Topline Results From Phase 3 Trial Of Xyngari - SEC Filing
15/04/2025 14:15
April 15 (Reuters) - Dermata Therapeutics Inc DRMA.O: DERMATA THERAPEUTICS INC - ANNOUNCES TOPLINE RESULTS FROM PHASE 3 TRIAL OF XYNGARI - SEC FILING Source text: [ID:n0001654954-25-004265] Further company coverage: DRMA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dermata Therapeutics
See all newsNASDAQ RESUMED AT 10:31 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:26 AM
Brief: Dermata Therapeutics - To Launch First Commercial Product Tome Foundational Treatment On August 25, 2026
Dermata Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dermata Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview